Sangamo Biosciences reported $447.4M in Current Assets for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acceleron Pharma XLRN:US $ 696.61M 21.16M
Alnylam Pharmaceuticals ALNY:US $ 2675.36M 49.8M
Amgen AMGN:US $ 24380M 5281M
Avrobio Inc AVRO:US 211.66M 21.86M
Bayer BAYN:GR 31.94B 506M
Biogen BIIB:US $ 7162.3M 21.4M
Biomarin Pharmaceutical BMRN:US $ 2311.57M 46.27M
Bluebird Bio BLUE:US $ 832.32M 71.2M
Gilead Sciences GILD:US $ 14200M 275M
GlaxoSmithKline GSK:LN 18.25B 688M
IONIS PHARMACEUT IONS:US $ 2156M 82.42M
Karyopharm Therapeutics KPTI:US $ 241.58M 31.92M
Novartis NOVN:VX 26.25B 2.45B
Omeros OMER:US $ 91.35M 21.05M
Sangamo Biosciences SGMO:US $ 447.4M 106.67M
Sarepta Therapeutics SRPT:US $ 2185.31M 79.91M
Ultragenyx Pharmaceutical RARE:US $ 846.88M 102.61M
Vertex Pharmaceuticals VRTX:US $ 8852.54M 395.03M
Ziopharm Oncology ZIOP:US $ 96.55M 7.15M